Peptide-Drug Conjugates (PDCs) Synthesis

Peptide–Drug Conjugates (PDCs) offer a practical approach to targeted delivery by combining receptor-specific peptides with functional payloads. This strategy helps improve targeting efficiency while reducing off-target effects, making PDCs increasingly valuable in both therapeutic and diagnostic research.

At Biorunstar, we support PDC projects from early design through synthesis and analytical validation, with a focus on reliability, flexibility, and clear communication throughout the process.

 

Our Core PDC Capabilities

1. Targeting Peptide Design & Synthesis

We provide custom synthesis of peptides with strong binding affinity toward specific receptors, commonly used in targeted delivery studies.

Typical examples include sequences such as RGD, cRGD, TAT, and GnRH.

Available modifications:

Cyclization (disulfide or amide bond)

N- or C-terminal modification

Incorporation of D-amino acids and non-natural amino acids for improved stability

 

2. Payload Conjugation & Labeling

We support conjugation of peptides with a range of research and drug-related payloads, depending on your application.

Cytotoxic / small-molecule payloads:

MMAE / MMAF

Camptothecin (CPT)

Osimertinib

Ciprofloxacin (CIP)

Fluorescent labeling (for imaging & tracking):

FITC, FAM

Cy3 / Cy5

BODIPY 630/650

Radiolabeling support:

Chelators such as DOTA and NOTA for radiotherapy or imaging studies

 

3. Linker Selection & Conjugation Strategies

Linker design plays a critical role in balancing stability and controlled release. We assist in selecting and implementing suitable linker systems based on your project goals.

Cleavable linkers:

pH-sensitive

Enzyme-cleavable (e.g., Val–Cit)

Disulfide-based

Non-cleavable linkers:

PEG-based

Alkyl chains for solubility and pharmacokinetic tuning

Conjugation methods:

Click chemistry (DBCO / Azide–Alkyne)

Thiol–maleimide (Cys-specific)

NHS ester (N-terminus or Lysine)

 

Featured Case Study

Osimertinib-Conjugated Peptide Synthesis

We have completed multiple projects involving the conjugation of Osimertinib (EGFR inhibitor) to targeting peptides, supporting targeted delivery and oncology-related research.

https://www.biorunstar.com/projects/osimertinib-conjugated-peptide.html

Camptothecin (CPT) & Ciprofloxacin (CIP) Labeled Peptide Synthesis

We have developed peptide conjugates based on the same targeting sequence, incorporating different payloads such as Camptothecin (CPT) and Ciprofloxacin (CIP) for diverse research applications, including oncology and antibacterial studies.

https://www.biorunstar.com/projects/cip-cpt-peptide-synthesis-case.html

 

Quality Assurance & Delivery

Every PDC order is subject to rigorous quality control to ensure the integrity of the conjugate:

HPLC & MS: Verification of purity (up to 98%) and molecular weight.

Solubility Testing: Ensuring the conjugate is suitable for your biological assays.

Stability Assessment: Basic stability data available upon request.

 

Request a Quote for Your PDC Project

Ready to move your research forward? Contact our technical team for a free consultation and a transparent quote.

Email: sales@biorunstar.com

View more cases: www.biorunstar.com/projects